Comparative Pharmacology
Head-to-head clinical analysis: BRIELLYN versus ENOVID E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIELLYN versus ENOVID E.
BRIELLYN vs ENOVID-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) that inhibits gonadotropin secretion, primarily suppressing ovulation and altering cervical mucus and endometrial lining.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
BRIELLYN (ethinyl estradiol / norethindrone) 1 tablet (0.035 mg ethinyl estradiol / 0.5 mg norethindrone) orally once daily at the same time each day.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
None Documented
None Documented
12-19 hours; clinical context: steady state reached in 3-5 days, dosing adjustment recommended in renal impairment
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Approximately 60% renal excretion of metabolites, 40% fecal/biliary elimination
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive